Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples

L Alemany; M Saunier; L Tinoco; B Quirós; I Alvarado-Cabrero; M Alejo; E A Joura; P Maldonado; J Klaustermeier; J Salmerón; C Bergeron; K U Petry; N Guimerà; O Clavero; R Murillo; C Clavel; V Wain; D T Geraets; R Jach; P Cross; C Carrilho; C Molina; H R Shin; V Mandys; A M Nowakowski; A Vidal; L Lombardi; H Kitchener; A R Sica; C Magaña-León; M Pawlita; W Quint; I G Bravo; N Muñoz; S de Sanjosé; F X Bosch; HPV VVAP study group

doi:10.1016/j.ejca.2014.07.018

Back

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples

Journal article

Peer reviewed

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples

L Alemany, M Saunier, L Tinoco, B Quirós, I Alvarado-Cabrero, M Alejo, E A Joura, P Maldonado, J Klaustermeier, J Salmerón, …

European journal of cancer (1990), Vol.50(16), pp.2846-2854

11/2014

DOI: 10.1016/j.ejca.2014.07.018

PMID: 25155250

Files and links (1)

url

https://ruj.uj.edu.pl/xmlui/handle/item/134094View

Open Access

Abstract

Aim This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide. Methods We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA25 system (version 1). A subset of 146 vaginal cancers was tested for p16INK4a expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance. Results HPV DNA was detected in 74% (95% confidence interval (CI): 70–78%) of invasive cancers and in 96% (95% CI: 92–98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16INK4a overexpression was found in 87% of HPV DNA positive vaginal cancer cases. Conclusions HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.

Aged

Carcinoma, Squamous Cell - complications

Carcinoma, Squamous Cell - epidemiology

Carcinoma, Squamous Cell - virology

Cross-Sectional Studies

Cyclin-Dependent Kinase Inhibitor p16 - metabolism

DNA, Viral - analysis

Female

Human papillomavirus 16 - isolation & purification

Humans

Immunoenzyme Techniques

International Cooperation

Middle Aged

Papillomaviridae - isolation & purification

Papillomavirus Infections - complications

Papillomavirus Infections - epidemiology

Papillomavirus Infections - virology

Poisson Distribution

Precancerous Conditions - epidemiology

Precancerous Conditions - virology

Prevalence

Regression Analysis

Retrospective Studies

Treatment Outcome

Vaginal Neoplasms - complications

Vaginal Neoplasms - epidemiology

Vaginal Neoplasms - virology

Details

Title: Subtitle: Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples
Creators: L Alemany - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: lalemany@iconcologia.net
M Saunier - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
L Tinoco - Hospital Oncológico, Quito, Ecuador
B Quirós - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
I Alvarado-Cabrero - Mexican Oncology Hospital, IMSS, Mexico, DF, Mexico
M Alejo - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital General de L'Hospitalet, Barcelona, Spain
E A Joura - Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria
P Maldonado - Instituto de Ginecologia da Universidad Federal Do Rio de Janeiro-UFRJ, Rio de Janeiro, Brazil
J Klaustermeier - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain
J Salmerón - Mexican Oncology Hospital, IMSS, Mexico, DF, Mexico
C Bergeron - Laboratoire Cerba, Department de Pathologie, Paris, France
K U Petry - Klinikum Wolfsburg, Wolfsburg, Germany
N Guimerà - DDL Diagnostic Laboratory, Rijswijk, The Netherlands
O Clavero - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
R Murillo - Instituto Nacional de Cancerología, Bogotá, Colombia
C Clavel - CHU Reims, Hopital Maison Blanche, Laboratoire Pol Bouin, Reims, France; INSERM UMR-S903, Reims, France
V Wain - WestMead Hospital, Sydney, Australia
D T Geraets - DDL Diagnostic Laboratory, Rijswijk, The Netherlands
R Jach - Jagiellonian University Medical College, Krakow, Poland
P Cross - Queen Elizabeth Hospital, Sheriff Hill, UK
C Carrilho - Faculty of Medicine, Eduardo Mondlane University and Maputo Central Hospital, Maputo, Mozambique
C Molina - Centro de Oncología Preventiva, Universidad de Chile, Santiago, Chile
H R Shin - National Cancer Center, Seoul, South Korea
V Mandys - Third Faculty of Medicine and Faculty Hospital King's Wineyards, Prague, Czech Republic
A M Nowakowski - Medical University of Lublin, Lublin, Poland
A Vidal - Hospital Universitari de Bellvitge, Barcelona, Spain
L Lombardi - Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva - CIESAR, Hospital General San Juan de Dios - HGSJDD, Guatemala, Guatemala
H Kitchener - Manchester Royal Infirmary, Manchester, United Kingdom
A R Sica - Laboratorio de Anatomia Patológica del Hospital de la Mujer, Montevideo, Uruguay
C Magaña-León - Instituto Potosino de Investigación Científica y Tecnológica, AC (IPICYT), San Luis Potosí, Mexico
M Pawlita - German Cancer Research Center (DKFZ), Heidelberg, Germany
W Quint - DDL Diagnostic Laboratory, Rijswijk, The Netherlands
I G Bravo - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
N Muñoz - Cancer Institute of Colombia, Colombia
S de Sanjosé - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain
F X Bosch - Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
HPV VVAP study group
Contributors: Charles F Lynch (Contributor) - University of Iowa, Epidemiology
Resource Type: Journal article
Publication Details: European journal of cancer (1990), Vol.50(16), pp.2846-2854
DOI: 10.1016/j.ejca.2014.07.018
PMID: 25155250
NLM abbreviation: Eur J Cancer
ISSN: 0959-8049
eISSN: 1879-0852
Language: English
Date published: 11/2014
Academic Unit: Epidemiology
Record Identifier: 9984214792702771

Metrics

18 Record Views

125 Times Cited - Web of Science